Premium
The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors
Author(s) -
WALSH BRIAN W.
Publication year - 2001
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2001.tb04015.x
Subject(s) - raloxifene , selective estrogen receptor modulator , estrogen , hormone replacement therapy (female to male) , medicine , endocrinology , lipoprotein , adverse effect , cholesterol , estrogen receptor , pharmacology , breast cancer , cancer , testosterone (patch)
A bstract : Raloxifene, a selective estrogen receptor modulator, favorably alters several markers of cardiovascular risk in healthy postmenopausal women. While many of its effects are similar to those of conventional hormone replacement therapy (HRT), there are also important differences. Raloxifene lowered low‐density lipoprotein cholesterol levels similarly to estrogen. However, raloxifene lacked the potentially beneficial effects of HRT on high‐density lipoprotein cholesterol levels and plasminogen activation inhibitor‐1, as well as the potentially adverse effects of HRT on triglycerides and C‐reactive protein. Raloxifene also had a potentially beneficial fibrinogen‐lowering effect not seen with conventional HRT. The net effect of these differences is unclear. Proof that raloxifene or HRT reduces the risk of heart disease must await the results of ongoing clinical trials with cardiovascular event end points.